Acemetacyna – skuteczność i bezpieczeństwo w praktyce klinicznej Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2017
Słowa kluczowe:
acemetacyna, cyklooksygenaza, bezpieczeństwo sercowo-naczyniowe
##plugins.themes.bootstrap3.article.main##
Abstrakt
Acemetacyna jest inhibitorem cyklooksygenazy o działaniu przeciwzapalnym oraz przeciwbólowym. W organizmie jest częściowo metabolizowana do indometacyny. Acemetacynę stosuje się w stanach zapalnych, takich jak reumatoidalne zapalenie stawów, leczeniu bólów związanych ze zmianami zwyrodnieniowymi kręgosłupa oraz bólów pooperacyjnych. Przewaga acemetacyny nad indometacyną wiąże się z większym bezpieczeństwem ze strony przewodu pokarmowego, natomiast dane dotyczące bezpieczeństwa ze strony układu sercowo-naczyniowego są ograniczone.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Postuła , M., & Berkowicz , T. (2017). Acemetacyna – skuteczność i bezpieczeństwo w praktyce klinicznej . Medycyna Faktów , 10(3(36), 262-266. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2136
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. FitzGerald G.A., Patrono C.: The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 2001; 345: 433-442.
2. Fries J.F.: Selective cyclooxygenase inhibition: promise for future NSAID therapy? Scand. J. Rheumatol. Suppl. 1996; 102: 1.
3. Bombardier C., Laine L., Reicin A. et al.; VIGOR Study Group: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 2000; 343: 1520-1528.
4. Amer M., Bead V.R., Bathon J. et al.: Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale. Cardiol. Rev. 2010; 18: 204-212.
5. Bresalier R.S., Sandler R.S., Quan H. et al.; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 2005; 352: 1092-1102.
6. Solomon S.D., McMurray J.J., Pfeffer M.A. et al.; Adenoma Prevention with Celecoxib (APC) Study Investigators: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 2005; 352: 1071-1080.
7. McGettigan P., Henry D.: Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633-1644.
8. García Rodríguez L.A., Tacconelli S., Patrignani P.: Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J. Am. Coll. Cardiol. 2008; 52: 1628-1636.
9. McGettigan P., Henry D.: Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011; 8: e1001098.
10. Trelle S., Reichenbach S., Wandel S. et al.: Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: c7086.
11. Bhala N., Emberson J., Merhi A. et al.; Coxib and traditional NSAID Trialists’ (CNT) Collaboration: Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013; 382: 769-779.
12. Fabule J., Adebajo A.: Comparative evaluation of cardiovascular outcomes in patients with osteoarthritis and rheumatoid arthritis on recommended doses of nonsteroidal anti-inflammatory drugs. Ther. Adv. Musculoskelet. Dis. 2014; 6: 111-130.
13. Scott P.A., Kingsley G.H., Scott D.L.: Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials. Eur. J. Heart Fail. 2008; 10: 1102-1107.
14. García Rodríguez L.A., Hernández-Díaz S.: Nonsteroidal anti-inflammatory drugs as a trigger of clinical heart failure. Epidemiology 2003; 14: 240-246.
15. Arte A., Scotti L., Varas-Lorenzo C. et al.: Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: Nested case-control study. BMJ 2016; 354: i4857.
16. Chavez-Pina A.E., McKnight W., Dicay M. et al.: Mechanizm underlying the anti-inflammatory activity and gastric safety of acemetacin. British J. Pharmacol. 2007; 152(6): 930-938.
17. Manchikanti L., Singh V., Falco F.J. et al.: Epidemiology of low back pain in adults. Neuromodulation 2014; 17 Supl. 2: 3-10.
18. Hinz B., Dorn C.P., Shen T.Y., Brune K.: Anti-inflammatory-antirheumatic drugs. W: Ullmann’s Encyclopedia of Industrial Chemistry. Tom A3, Wiley-VCH, Weinheim, 2002.
19. Rantudil Forte – Charakterystyka Produktu Leczniczego.
20. Rantudil Retard – Charakterystyka Produktu Leczniczego.
21. Moore R.A., Derry S., McQuay H.J.: Single dose oral acemetacin for acute postoperative pain in adults. Cochrane Database Syst. Rev. 2009; (3): CD007589.
22. Laws D.: Double blind parallel group investigation in general practice of the efficacy and tolerability of acemetacin, in comparison with diclofenac, in patients suffering with acute low back pain. British J. Clin. Res. 1994; 5: 55-64.
23. VanderPluym J.: Indomethacin-responsive headaches. Curr. Neurol. Neurosci. Rep. 2015; 15(2): 516.
24. Nicpoń K.J., Nicpoń K.W., Jaroszuk-Nicpoń J.: Prophylaxis of hemicrania continua: Three cases effectively treated with acemethacin. Cephalalgia 2010; 31(5): 625-627.
25. Uncu H.: A comparison of low-molecular-weight heparin and combined therapy of low-molecular-weight heparin with an anti-inflammatory agent in the treatment of superficial vein thrombosis. Phlebology 2009; 24(2): 56-60.
2. Fries J.F.: Selective cyclooxygenase inhibition: promise for future NSAID therapy? Scand. J. Rheumatol. Suppl. 1996; 102: 1.
3. Bombardier C., Laine L., Reicin A. et al.; VIGOR Study Group: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 2000; 343: 1520-1528.
4. Amer M., Bead V.R., Bathon J. et al.: Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale. Cardiol. Rev. 2010; 18: 204-212.
5. Bresalier R.S., Sandler R.S., Quan H. et al.; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 2005; 352: 1092-1102.
6. Solomon S.D., McMurray J.J., Pfeffer M.A. et al.; Adenoma Prevention with Celecoxib (APC) Study Investigators: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 2005; 352: 1071-1080.
7. McGettigan P., Henry D.: Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633-1644.
8. García Rodríguez L.A., Tacconelli S., Patrignani P.: Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J. Am. Coll. Cardiol. 2008; 52: 1628-1636.
9. McGettigan P., Henry D.: Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011; 8: e1001098.
10. Trelle S., Reichenbach S., Wandel S. et al.: Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: c7086.
11. Bhala N., Emberson J., Merhi A. et al.; Coxib and traditional NSAID Trialists’ (CNT) Collaboration: Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013; 382: 769-779.
12. Fabule J., Adebajo A.: Comparative evaluation of cardiovascular outcomes in patients with osteoarthritis and rheumatoid arthritis on recommended doses of nonsteroidal anti-inflammatory drugs. Ther. Adv. Musculoskelet. Dis. 2014; 6: 111-130.
13. Scott P.A., Kingsley G.H., Scott D.L.: Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials. Eur. J. Heart Fail. 2008; 10: 1102-1107.
14. García Rodríguez L.A., Hernández-Díaz S.: Nonsteroidal anti-inflammatory drugs as a trigger of clinical heart failure. Epidemiology 2003; 14: 240-246.
15. Arte A., Scotti L., Varas-Lorenzo C. et al.: Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: Nested case-control study. BMJ 2016; 354: i4857.
16. Chavez-Pina A.E., McKnight W., Dicay M. et al.: Mechanizm underlying the anti-inflammatory activity and gastric safety of acemetacin. British J. Pharmacol. 2007; 152(6): 930-938.
17. Manchikanti L., Singh V., Falco F.J. et al.: Epidemiology of low back pain in adults. Neuromodulation 2014; 17 Supl. 2: 3-10.
18. Hinz B., Dorn C.P., Shen T.Y., Brune K.: Anti-inflammatory-antirheumatic drugs. W: Ullmann’s Encyclopedia of Industrial Chemistry. Tom A3, Wiley-VCH, Weinheim, 2002.
19. Rantudil Forte – Charakterystyka Produktu Leczniczego.
20. Rantudil Retard – Charakterystyka Produktu Leczniczego.
21. Moore R.A., Derry S., McQuay H.J.: Single dose oral acemetacin for acute postoperative pain in adults. Cochrane Database Syst. Rev. 2009; (3): CD007589.
22. Laws D.: Double blind parallel group investigation in general practice of the efficacy and tolerability of acemetacin, in comparison with diclofenac, in patients suffering with acute low back pain. British J. Clin. Res. 1994; 5: 55-64.
23. VanderPluym J.: Indomethacin-responsive headaches. Curr. Neurol. Neurosci. Rep. 2015; 15(2): 516.
24. Nicpoń K.J., Nicpoń K.W., Jaroszuk-Nicpoń J.: Prophylaxis of hemicrania continua: Three cases effectively treated with acemethacin. Cephalalgia 2010; 31(5): 625-627.
25. Uncu H.: A comparison of low-molecular-weight heparin and combined therapy of low-molecular-weight heparin with an anti-inflammatory agent in the treatment of superficial vein thrombosis. Phlebology 2009; 24(2): 56-60.